Curidium has developed a proprietary and unique technology, known as Homomatrix^®. It can identify distinct patient subgroups, leading to the development of diagnostic tools to separate the groups. Each group may be associated with different drug targets, and thus candidate drugs may be developed as effective, subgroup specific drug treatments. Homomatrix^® has applications in many chronic human heterogeneous diseases.

Homomatrix^® is a sophisticated data analysis system that examines large amounts of human biological data, such as gene (mRNA) expression data. Homomatrix^® has adopted principles of epidemiology, human genetics and molecular pharmacology to analyze biological data from disease affected and control donors.

On a genome-wide scale, using gene-expression microarrays, Homomatrix^® may be applied to identify underlying disease mechanisms, including signaling pathways and potentially novel gene-gene associations. The combined findings, covering a large part of the human genome, segregate the patient population studied into subgroups, each with a distinct gene expression profile or molecular signature. Although the method has strong bioinformatics and biostatistics components, its uniqueness stems from a collection of proprietary pattern recognition tools, specific sequences of mathematical algorithms and customized statistical methods used to analyze human biological datasets.

Homomatrix^® appears to have significant advantages over techniques designed to analyze biological data, as it is able to provide detailed analysis of the molecular differences between patient subgroups within heterogeneous patient populations.